While the presence of eosinophils in the skin lesions of bullous pemphigoid is well documented, the chemotactic factors responsible for eosinophil recruitment into the tissue still remain to be defined. In this study, eotaxin and interleukin-5 (IL-5) concentrations were determined in the blister fluid and sera of patients with bullous pemphigoid (acute and remission phase, n=6) in comparison with normal healthy controls (n=6) using the enzyme-linked immunosorbent assay (ELISA) technique. Eotaxin and IL-5 levels were increased in the blister fluid compared with the acute and remission phase sera, as well as compared with the sera of normal controls. In addition, immunoreactivicy for eotaxin was predominantly found in the inflammatory cell infiltrate of lesional bullous pemphigoid biopsy specimens. In conclusion, the data provide evidence that co-operation of eotaxin and IL-5 may play an essential role in activating and recruiting eosinophils, which ultimately contribute to the tissue damage in bullous pemphigoid. 

Key words: chemokine; cytokine; immunohistochemistry; ELISA.

(MATERIALS AND METHODS

Subjects

Six Caucasian patients with recent-onset BP (3 males and 3 females, mean age 74, range 65–84 years) and 6 age- and sex-matched healthy controls were included in the study after their informed consent was obtained. The diagnosis was based on typical clinical presentation, histology, and direct and indirect immunofluorescence findings.

Collection of blister fluid and sera

Blister fluid was obtained from tense blisters, approximately 24 h old. Acute-phase sera were obtained on the same day as blister puncture. At this time, bullous eruptions covered approximately 30–40% of the body surface. Remission-phase sera were collected approximately 3–4 months later, when the patients exhibited no blisters and were receiving treatment with varying doses of prednisone (10–15 mg) with or without azathioprine (50–100 mg). Blister fluids and sera were stored in aliquots at −20°C until analysis.

Skin specimens

Punch biopsy specimens of 5 mm diameter were taken from the edge of a fresh (<24 h old) blister during the acute phase of the disease. Normal skin from 6 non-atopic controls was obtained from patients undergoing reconstructive surgery. Tissue samples were snap-frozen in tissue-embedding medium using isopentane precooled in liquid nitrogen and stored at −70°C until used.

Analysis of cytokines and eosinophilic cationic protein

Human eotaxin was measured in blister fluid and sera using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Human IL-5 was detected with a cytokine-specific sandwich ELISA using monoclonal antibody pairs (native capture mAb and biotinylated detecting mAb), all obtained from PharMingen Beckon Dickinson, Mountain View, CA, USA as described previously (11). ECP was measured using a fluoroenzyme immunoassay (UniCAP® ECP, Pharmacia, Uppsala, Sweden). All analyses were performed in duplicate. The detection limits of the assays were 3 pg/ml for eotaxin, 5 pg/ml for IL-5 and 0.5 µg/l for ECP.

Increasing evidence indicates co-operation between eotaxin and interleukin-5 (IL-5) in inducing optimal activation and recruitment of eosinophils (9, 10). The present study was therefore designed to study the expression of both factors in the blister fluid and sera of patients suffering from BP.
Immunohistochemistry

Immunostaining of skin sections was performed using (mouse monoclonal) anti-eotaxin antibodies (clone 3C7, concentration 50 μg/ml; PharMingen/Beckon Dickinson) according to the avidin–biotin complex/alkaline phosphatase (ABC/AP) method. Sections of 5 μm were fixed in 2% formaldehyde for 8 min. Slides were then incubated overnight with the primary antibody, followed by a biotinylated rabbit-anti-mouse immunoglobulin G (IgG) (dilution 1:200, E0413; DAKO) and thereafter with ABC/AP (dilution 1:50; K0376; DAKO). Finally, all sections were developed in new fuchsin–napthol (DAKO®; DAKO). Substitution of the primary antibody with isotype-matched IgG and omission of the primary antibody served as negative controls.

Evaluation of skin sections

The numbers of eosinophils on skin sections stained with haematoxylin & eosin (H&E) and eotaxin-positive cells were assessed on 10–15 fields of each section at 400 × magnification with a Leitz Dialux 20EB and counted using a 0.09 mm² grid. The number of positive cells (mean ± SEM) per mm² was calculated.

Statistical analysis

Statistical analysis was performed using the Mann–Whitney U-test for the unpaired and Wilcoxon rank test for the paired samples.

RESULTS

Increased levels of eosinophils, eosinophilic proteins and interleukin-5 protein in bullous pemphigoid

Eosinophil numbers in blood and tissue as well as ECP values are summarized in Table I. In comparison to normal controls, a significantly increased number of eosinophils in the blood (p < 0.004) and raised serum levels of ECP (p < 0.004) were observed in the patients with BP, which corresponds to previous reports (12). In addition, a significantly increased number of eosinophils per mm² was documented in the H&E-stained BP skin sections (p < 0.002) compared with normal skin.

As also demonstrated in Table I, markedly increased levels of eotaxin were detected in the blister fluid of patients with BP compared with their sera in the acute phase and remission phase, as well as with sera from healthy controls. Eotaxin levels in the sera of the acute phase were also higher than those of the remission phase or those from healthy controls, although the differences were just not statistically significant (p = 0.055 and p = 0.058, respectively).

Levels of IL-5 were high in the blister fluid (1492 ± 782.1 pg/ml) and in the sera of the acute-phase patients with BP (55.5 ± 49 pg/ml) (not shown in Table I). The serum levels of IL-5 were below the detection limits (< 5 pg/ml) during remission and in the normal controls.

Enhanced immunoreactivity for eotaxin in bullous pemphigoid skin lesions

Localization of eotaxin is shown as a representative example in Fig. 1. Positive immunostaining for eotaxin was predominantly detected in the inflammatory cell infiltrate in the dermis of the BP lesions. Some endothelial cells and fibroblasts as well as a few eosinophils and basal keratinocytes also focally demonstrated immunoreactivity for eotaxin. A significantly (p < 0.002) higher mean number of positive cells per mm² was found in the BP lesions (93.8 ± 11.4) compared with normal skin (10.2 ± 0.8). No positive staining was seen on substitution of the primary antibody with an isotype-matched IgG (not shown).

DISCUSSION

The results demonstrate that both eotaxin and IL-5 levels are markedly increased in skin blisters of patients with BP compared with the sera of the same patients and healthy controls. In addition, immunohistochemical staining of lesional skin biopsies revealed enhanced expression of eotaxin in BP, predominantly within the inflammatory cell infiltrate.

Eotaxin is considered to be an important chemokine for the recruitment and degranulation of eosinophils (9). Recent studies have demonstrated an increased expression of eotaxin in diseases with eosinophilic infiltration such as bronchial asthma (13–15), chronic sinusitis (16), inflammatory bowel disease (17) and atopic dermatitis (18). The enhanced expression of eotaxin, particularly in the blister fluid of BP, indicates that this chemokine may also play an important role in the pathomechanism of this autoimmune bullous skin disease by recruiting and activating eosinophils.

Immunoreactivity for eotaxin was mainly observed in the mononuclear cell infiltrate, indicating that macrophages and T-cells could be a source of eotaxin. In the present study, double immunostaining experiments to identify precisely these mononuclear cells were not feasible. However, recent data on allergen-induced late-phase cutaneous responses indeed indi-

Table 1. Eosinophilic cationic protein, eosinophils and eotaxin in blood, skin biopsy specimens and blister fluid

<table>
<thead>
<tr>
<th></th>
<th>Bullous pemphigoid (n=6)</th>
<th>Controls (n=6)</th>
<th>p-Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECP (μg/l) in serum</td>
<td>29 ± 7.9</td>
<td>5.6 ± 1.2</td>
<td>&lt;0.004</td>
</tr>
<tr>
<td>Eosinophils (10^7/l) in blood</td>
<td>1.1 ± 0.38</td>
<td>0.1 ± 0.04</td>
<td>&lt;0.004</td>
</tr>
<tr>
<td>Eosinophils/mm² skin section</td>
<td>82.8 ± 14.5</td>
<td>0.5 ± 0.3</td>
<td>&lt;0.002</td>
</tr>
<tr>
<td>Eotaxin (pg/ml) in serum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute phase:</td>
<td>215 ± 46.2</td>
<td>149.3 ± 12</td>
<td>NS</td>
</tr>
<tr>
<td>Remission phase:</td>
<td>131.8 ± 39.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eotaxin (pg/ml) in blister fluid</td>
<td>457.6 ± 56.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are shown as means ± SEM.
NS: not significant.
cate that both CD68+ macrophages and CD3+ T-cells are capable of producing eotaxin (19).

IL-5 is known to be a key factor in the differentiation and activation of eosinophils. In accordance with previous reports (20 – 22), levels of IL-5 were also markedly raised in the blister fluid and acute phase sera of these BP patients. These data point to a synergistic effect of eotaxin and IL-5 on the maturation, activation and recruitment of eosinophils in BP. Therefore, it is most likely that eotaxin in co-operation with IL-5 promotes the maturation and activation of eosinophils in the bone marrow as well as their rapid release into the circulation (9). Subsequently, increased numbers of eosinophils are attracted into the skin via up-regulation of eotaxin at the site of inflammation, where elevated levels of IL-5 further enhance the activation and survival of these cells.

Besides IL-5, other type 2 cytokines such as IL-4, IL-10 and IL-13 have also been reported to be up-regulated in BP (23). These data suggest a dominant recruitment of T-helper (Th2) lymphocytes within the inflammatory cell infiltrate, although other proinflammatory cytokines such as tumour necrosis factor-α (TNFα) and interferon-γ have also been reported (24). The eotaxin receptor CCR3 has been shown to be selectively expressed on some Th2 lymphocytes (5, 6). Besides its action on eosinophils, eotaxin might therefore also substantially contribute to the recruitment of Th2 lymphocytes into BP lesions. In turn, this mechanism could be of particular relevance to the in situ up-regulation of eotaxin, since IL-4 and IL-13, together with other proinflammatory cytokines such as TNFα, have been reported to stimulate the production of eotaxin (25, 26). Furthermore, IL-5 has also been shown to up-regulate CCR3 on eosinophils (27), which again could amplify the recruitment of this cell type to the site of eotaxin expression. Thus, a complex cascade of positive feedback mechanisms involving eotaxin and IL-5 may help to sustain inflammation in BP.

In conclusion, the results provide further evidence for cooperation between eotaxin and IL-5 in the recruitment and activation of eosinophils and thus suggest an important role for these factors in the pathogenesis of BP.

ACKNOWLEDGEMENTS

We thank J. Mirkovitch and A. Urwyler for excellent technical help. Supported by Swiss National Science Foundation grant 32-48885.96, SCORE B (to N.Y.) and SNF no. 3100-053000 (to C.A.D.).

REFERENCES


Fig. 1. Eotaxin immunoreactivity in bullous pemphigoid (BP) and normal skin. Skin sections from 1 patient with BP and 1 healthy control are shown as representative examples. Few eotaxin positive cells are detected in the dermis of normal skin (a). In contrast, an increased number of cells positive for eotaxin is present predominantly in the dermis of BP skin lesions (b). ABC/AP method, original magnification ×250.


